Doximity Inc is a digital platform designed specifically for medical professionals, primarily physicians, to enhance communication and collaboration within the healthcare community. The platform provides a range of tools and resources, including secure messaging, telehealth services, and access to a network of healthcare professionals, allowing doctors to connect with each other and stay updated on medical news and developments. Additionally, Doximity offers features such as electronic faxing, a comprehensive directory of healthcare providers, and opportunities for continuing medical education, all aimed at improving clinical workflows and ultimately enhancing patient care. Read More
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Doximity’s fourth quarter results for 2025 were met with a sharp negative market reaction, as management cited a combination of delayed pharmaceutical industry budgets and a notable increase in AI-related infrastructure spending as primary factors behind underwhelming outcomes. CEO Jeffrey Tangney pointed to record engagement across the platform, particularly in workflow and AI tools, but acknowledged that “client uncertainty” stemming from late-signed government pricing agreements caused several top pharma customers to delay or reduce upfront spending. Management also highlighted that the majority of revenue growth came from existing customers, with a 10% increase in high-value accounts, but also noted that elevated investments in AI pressured margins.
Hitting a new 52-week low can be a pivotal moment for any stock.
These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
The digital healthcare landscape faced a harsh reality check on February 6, 2026, as shares of Doximity, Inc. (NYSE: DOCS) plummeted 17% in early trading. Despite reporting fiscal third-quarter results that surpassed analyst estimates for both revenue and earnings, the professional network for physicians issued a tepid outlook for the
Multiple brokerages cut their price target on the stock after Doximity reported a fall in third-quarter earnings and a soft fourth-quarter revenue outlook.
Medical professional network Doximity (NYSE:DOCS) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 9.8% year on year to $185.1 million. On the other hand, next quarter’s revenue guidance of $143.5 million was less impressive, coming in 5.2% below analysts’ estimates. Its non-GAAP profit of $0.46 per share was 2.9% above analysts’ consensus estimates.
Medical professional network Doximity (NYSE:DOCS) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 9.8% year on year to $185.1 million. On the other hand, next quarter’s revenue guidance of $143.5 million was less impressive, coming in 5.2% below analysts’ estimates. Its non-GAAP profit of $0.46 per share was 2.9% above analysts’ consensus estimates.
A number of stocks fell in the afternoon session after the "AI replacement" narrative reached a fever pitch following the release of new models from Anthropic and OpenAI.
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, announced today that Doximity Dialer has been named the #1 Telehealth Video Conferencing Platform in the 2026 Best in KLAS Report. This is the fifth consecutive year that Doximity has earned the top spot, underscoring its position as a trusted, long-term partner for physicians and health systems.
Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 third quarter ended December 31, 2025.
